Notícias

Investors named Johnson & Johnson, Merck, Pfizer, AbbVie, Eli Lilly and Bristol Myers as possible bidders.

Earlier this week, SELLAS Life Sciences Group highlighted that its REGAL Phase 3 trial of galinpepimut-S (GPS) in acute myeloid leukemia has reached 78 of the 80 required overall survival events, bringing the pivotal data readout within sight. Investor interest has also been shaped by amended executive employment agreements that include change-of-control benefits, feeding speculation about potential corporate developments alongside the awaited GPS results. With the REGAL Phase 3 GPS data...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet the stock currently screens as expensive on broad valuation checks. This sets up a clear tension between recent share price strength and what the fundamentals suggest about value. Over 3 years, the stock has returned close to 7x, which puts extra focus on whether that gain is supported by fundamentals or mainly by sentiment. Expectations for strong revenue and earnings growth, combined with a sizeable shelf registration...

SELLAS Life Sciences Group (SLS) is drawing focused attention as its Phase 3 trial for galinpepimut-S in acute myeloid leukemia approaches the required events for an overall survival readout, a key catalyst for the stock. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.19, SELLAS Life Sciences Group has seen a 69.97% 1 month share price return and a 203.22% year to date share price return. The 1 year total shareholder return is very large, signaling that...

Sellas Life Sciences bounced back by 12.26 percent on Friday to close at $13.19 apiece, as investors positioned portfolios ahead of a potentially company-defining clinical data release, supported by takeover speculations and growing institutional interest. The company is expected to report data from the phase 3 study evaluating its Galinpepimut-S (GPS) treatment candidate in patients […]

CEO Angelos Stergiou said he will discuss “novel clinical developments” involving GPS and SLS009 on Fox & Friends.

J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.

CEO Angelos Stergiou said slower event accrual may signal a “highly effective active arm.”

SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is one of the 10 Best Performing American Stocks in June 2026. On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to $25 from $10 and kept a Buy rating on the shares. Molloy said the firm […]

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.

CEO Angelos M. Stergiou addressed concerns over the company’s trial to treat acute myeloid leukemia.

Gamma Investing cut its SLS stake by 259 shares, or 32%, holding 556 shares worth about $8,210 as of June 30.

Traders are watching for the 80th event, data lock and topline results, while some are also speculating about potential M&A.

SELLAS Life Sciences (SLS) has surged 550% in the past year, driven by technical momentum and speculative trading. SLS currently has no revenue, with all products in development or clinical trials, making the stock highly speculative. Technical indicators are overwhelmingly bullish, but high short interest highlights significant risk. Sentiment is...

First Financial Bank also held 10,000 SLS shares, valued at $147,600.

Endpoint Area listed Nov. 30 as the expected catalyst timing for Sellas’ Phase 3 GPS trial.

SELLAS Life Sciences Group stock has surged over the past three years, yet its low overall value score and rich market multiples leave investors weighing a strong price run against signals that the shares may already be pricing in a lot of good news. A roughly 8.5x return over 3 years places SELLAS Life Sciences Group among the stronger movers in biotech, which can heighten the risk that expectations get ahead of fundamentals. Anticipation around the Phase 3 REGAL AML trial readout and...

Buyout chatter is building after change-of-control updates and a market-cap surge to over $1.5 billion.

In recent days, SELLAS Life Sciences Group updated employment and severance agreements for key executives while its Phase 3 REGAL trial in acute myeloid leukemia neared final overall survival analysis, with 78 of 80 required events reached. These enhanced change‑of‑control terms, combined with the late‑stage status of galinpepimut‑S and early‑stage CDK9 inhibitor SLS009, have intensified market discussion about potential acquisition interest and the company’s long‑term oncology...

SELLAS Life Sciences Group (NasdaqCM:SLS) has amended executive employment and severance agreements tied to a potential change in control. The move comes as the company approaches final analysis of its pivotal Phase 3 acute myeloid leukemia (AML) immunotherapy trial. These contract changes are increasing speculation around potential merger or acquisition activity involving SELLAS Life Sciences. SELLAS Life Sciences Group is drawing renewed investor attention as its updated change in control...

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the 10 Stocks Investors Are Chasing Right Now. SELLAS Life Sciences extended its winning streak to an 8th straight session on Monday to soar to a new record high, as investors resumed buying positions after hinting at a potential takeover. In intra-day trading, the stock rocketed […]

Sellas Life Sciences, BlackBerry, and Ouster rallied to 52-week highs on Monday as investors rotated into the companies amid positive catalysts.

Recently updated change-of-control terms also fueled buyout chatter by outlining executive payouts and full equity acceleration related to a change in control.

Is SLS a good stock to buy? We came across a bullish thesis on SELLAS Life Sciences Group, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on SLS. SELLAS Life Sciences Group, Inc.’s share was trading at $9.07 as of June 23rd. SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical […]

XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.

Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.

SLS short interest climbed to nearly 33% of the float as of June 15, compared to 28.4% at the beginning of the year.

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the 9 Stocks Winning by Double Digits. Sellas Life Sciences extended its winning streak to a 6th straight session on Thursday, climbing 14.83 percent to end at $10.53 apiece, following a regulatory filing that hinted at a potential acquisition. In a disclosure, Sellas Life Sciences Group […]

The company updated the severance agreements for three of its top executives, including the CEO.